摘要
目的研究应用凯力康(注射用尤瑞克林)进行静脉滴注药物治疗对急性脑梗死的治疗效果。方法统计近年来以急诊方式入院的110例患者的临床病情及整体治疗情况,将全部患者随机、平均分配成两组且两者唯一区别为治疗组加用凯力康进行静脉药物滴注治疗。评定药物治疗前后两组患者治疗、恢复的整体效果并进行统计学分析。结果两组患者通过药物治疗,各项临床指标均较用药前得到明显改善,通过统计学分析证实治疗组较对照组具有更大的改善程度,且差异有统计学意义。结论凯力康对于改善急性脑梗死患者病情具有较好的治疗效果,值得临床推广应用。
Objective To study the clinic efficacy of Kallidinogenase（ Human Urinary Kailidinogenase） in treatment of patients with acute cerebral infarction. Methods The clinic situation in a total of 110 patients with acute cerebral infarction from emergency room in recent years were analyzed. All patients were randomly divided into 2 groups. The only difference between the two groups was the using of kallidinogenase in treatment group. The overall effect of treatment and recovery in two groups were statistically analyzed. Results Through the conventional treatment,the two scores improved significantly. Through the statistical analysis,the treatment group had a better improvement than the control group. the differences had statistical significance. Conclusions Kallidinogenase can notably improve the condition of patients with acute cerebral infarction. It has high value in clinical application.
出处
《航空航天医学杂志》
2016年第7期814-817,共4页
Journal of Aerospace medicine
关键词
凯力康
急性脑梗死
疗效研究
Human Urinary Kailidinogenase
Acute cerebral infarction
Efficacy studies
